Arcutis Biotherapeutics, Inc., a biopharmaceutical company based in Westlake Village, California and listed on Nasdaq as ARQT, has recently granted a total of 61,000 restricted stock units (RSUs) of its common stock to 9 newly onboarded employees. This decision was made by the Compensation Committee of Arcutis’ Board of Directors and falls under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan. The grant date for these RSUs was July 1, 2026, and it serves as a significant inducement for the new employees to commence their roles at Arcutis. This move aligns with Nasdaq Listing Rule 5635(c)(4) regarding inducements for new hires.